BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24173000)

  • 1. Riociguat approved for pulmonary hypertension.
    Traynor K
    Am J Health Syst Pharm; 2013 Nov; 70(22):1960. PubMed ID: 24173000
    [No Abstract]   [Full Text] [Related]  

  • 2. First-in-class guanylate cyclase stimulator approved for PAH.
    Guha M
    Nat Biotechnol; 2013 Dec; 31(12):1064. PubMed ID: 24316627
    [No Abstract]   [Full Text] [Related]  

  • 3. Riociguat: first global approval.
    Conole D; Scott LJ
    Drugs; 2013 Nov; 73(17):1967-75. PubMed ID: 24218053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Hill NS; Rahaghi FF; Sood N; Frey R; Ghofrani HA
    Respir Med; 2017 Aug; 129():124-129. PubMed ID: 28732819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
    Lian TY; Jiang X; Jing ZC
    Drug Des Devel Ther; 2017; 11():1195-1207. PubMed ID: 28458514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Riociguat for the treatment of pulmonary hypertension.
    Hambly N; Granton J
    Expert Rev Respir Med; 2015; 9(6):679-95. PubMed ID: 26599488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Riociguat - a stimulator of soluble guanylate cyclase: a new mode of action helps patients with pulmonary hypertension].
    Kreutzkamp B
    Med Monatsschr Pharm; 2013 Dec; 36(12):442-7. PubMed ID: 24450268
    [No Abstract]   [Full Text] [Related]  

  • 8. Riociguat for pulmonary hypertension.
    Cannon JE; Pepke-Zaba J
    Expert Rev Clin Pharmacol; 2014 May; 7(3):259-70. PubMed ID: 24580082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Riociguat: a novel new drug for treatment of pulmonary hypertension.
    Makowski CT; Rissmiller RW; Bullington WM
    Pharmacotherapy; 2015 May; 35(5):502-19. PubMed ID: 26011143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Dasgupta A; Bowman L; D'Arsigny CL; Archer SL
    Clin Pharmacol Ther; 2015 Jan; 97(1):88-102. PubMed ID: 25670386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Marra AM; Egenlauf B; Ehlken N; Fischer C; Eichstaedt C; Nagel C; Bossone E; Cittadini A; Halank M; Gall H; Olsson KM; Lange TJ; GrĂ¼nig E
    Int J Cardiol; 2015 Sep; 195():19-26. PubMed ID: 26011408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Bishop BM
    Am J Health Syst Pharm; 2014 Nov; 71(21):1839-44. PubMed ID: 25320133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and effectiveness of riociguat to treat chronic thromboembolic pulmonary hypertension.
    DeSouza SA; Preston IR
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):467-76. PubMed ID: 25797801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Riociguat (Adempas) for pulmonary hypertension.
    Med Lett Drugs Ther; 2014 Mar; 56(1437):17-9. PubMed ID: 24589497
    [No Abstract]   [Full Text] [Related]  

  • 15. Riociguat for pulmonary hypertension.
    Ghofrani HA; Voswinckel R; Gall H; Schermuly R; Weissmann N; Seeger W; Grimminger F
    Future Cardiol; 2010 Mar; 6(2):155-66. PubMed ID: 20230258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Riociguat for the treatment of pulmonary hypertension.
    Meis T; Behr J
    Expert Opin Pharmacother; 2014 Nov; 15(16):2419-27. PubMed ID: 25260791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Riociguat recommended by CHMP for approval in the EU for use in two forms of pulmonary hypertension.
    Dowdall M
    Future Cardiol; 2014 Mar; 10(2):163. PubMed ID: 24883440
    [No Abstract]   [Full Text] [Related]  

  • 18. Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration.
    Hill NS; Badesch D; Benza RL; D'Eletto TA; Farber HW; Gomberg-Maitland M; Hassoun PM; Preston I
    Ann Am Thorac Soc; 2015 Feb; 12(2):269-73. PubMed ID: 25590376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy.
    Ghofrani HA; Grimminger F
    Eur Respir Rev; 2009 Mar; 18(111):35-41. PubMed ID: 20956121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecule of the month. Riociguat.
    Drug News Perspect; 2009 Apr; 22(3):167. PubMed ID: 19440559
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.